<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31135059</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9896</ISSN><JournalIssue CitedMedium="Internet"><Volume>249</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of pathology</Title><ISOAbbreviation>J Pathol</ISOAbbreviation></Journal><ArticleTitle>Mitochondrial dysfunction and role of harakiri in the pathogenesis of myositis.</ArticleTitle><Pagination><StartPage>215</StartPage><EndPage>226</EndPage><MedlinePgn>215-226</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/path.5309</ELocationID><Abstract><AbstractText>The etiology of myositis is unknown. Although attempts to identify viruses in myositis skeletal muscle have failed, several studies have identified the presence of a viral signature in myositis patients. Here we postulate that in individuals with susceptible genetic backgrounds, viral infection alters the epigenome to activate the pathological pathways leading to disease onset. To identify epigenetic changes, methylation profiling of Coxsackie B infected human myotubes and muscle biopsies from polymyositis (PM) and dermatomyositis (DM) patients were compared to changes in global transcript expression induced by in vitro Coxsackie B infection. Gene and protein expression analysis and live cell imaging were performed to examine the mechanisms. Analysis of methylation and gene expression changes identified that a mitochondria-localized activator of apoptosis&#xa0;-&#xa0;harakiri (HRK) - is upregulated in myositis skeletal muscle cells. Muscle cells with higher HRK expression have reduced mitochondrial potential and poor ability to repair from injury as compared to controls. In cells from myositis patient toll-like receptor 7 (TLR7) activates and sustains high HRK expression. Forced over expression of HRK in healthy muscle cells is sufficient to compromise their membrane repair ability. Endurance exercise that is associated with improved muscle and mitochondrial function in PM and DM patients decreased TLR7 and HRK expression identifying these as therapeutic targets. Increased HRK and TLR7 expression causes mitochondrial damage leading to poor myofiber repair, myofiber death and muscle weakness in myositis patients and exercise induced reduction of HRK and TLR7 expression in patients is associated with disease amelioration. &#xa9; 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</AbstractText><CopyrightInformation>&#xa9; 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boehler</LastName><ForeName>Jessica F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Center for Genetic Medicine Research, Children's National Health System, Washington, DC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Biomedical Sciences, George Washington University, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horn</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Genetic Medicine Research, Children's National Health System, Washington, DC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Biomedical Sciences, George Washington University, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novak</LastName><ForeName>James S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-9989-8724</Identifier><AffiliationInfo><Affiliation>Center for Genetic Medicine Research, Children's National Health System, Washington, DC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genomics and Precision Medicine, George Washington University School of Medicine, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghimbovschi</LastName><ForeName>Svetlana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Genetic Medicine Research, Children's National Health System, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundberg</LastName><ForeName>Ingrid E</ForeName><Initials>IE</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, Karolinska Institutet, Solna, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology, Karolinska Universitetssjukhuset, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexanderson</LastName><ForeName>Helene</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Function Area Occupational Therapy and Physical Therapy, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Physical Therapy, Department of NVS, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alemo Munters</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Function Area Occupational Therapy and Physical Therapy, Karolinska University Hospital and Swedish Rheumatism Association, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaiswal</LastName><ForeName>Jyoti K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Center for Genetic Medicine Research, Children's National Health System, Washington, DC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genomics and Precision Medicine, George Washington University School of Medicine, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagaraju</LastName><ForeName>Kanneboyina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Genetic Medicine Research, Children's National Health System, Washington, DC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K26 OD011171</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AR55686</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HD090257</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Swedish Rheumatism Association</Agency><Country>International</Country></Grant><Grant><GrantID>R21 AI128248</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56NS097229-01</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS097229</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Stockholm County Council (ALF project)</Agency><Country>International</Country></Grant><Grant><GrantID>K2014-52X-14045-14-3</GrantID><Agency>Swedish Research Council</Agency><Country>International</Country></Grant><Grant><GrantID>R21AI128248</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR055686</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>TI_</Acronym><Agency>Telethon</Agency><Country>Italy</Country></Grant><Grant><GrantID>W81XWH-11-1-0809</GrantID><Agency>Myositis Association and The US Department of Defense</Agency><Country>International</Country></Grant><Grant><GrantID>R21AI128248-02</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>King Gustaf V 80&#x2009;year Foundation</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Pathol</MedlineTA><NlmUniqueID>0204634</NlmUniqueID><ISSNLinking>0022-3417</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484586">HRK protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495348">TLR7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051199">Toll-Like Receptor 7</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003882" MajorTopicYN="N">Dermatomyositis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008931" MajorTopicYN="N">Mitochondria, Muscle</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053580" MajorTopicYN="N">Muscle Strength</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032448" MajorTopicYN="N">Myoblasts, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010807" MajorTopicYN="N">Physical Endurance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017285" MajorTopicYN="N">Polymyositis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051199" MajorTopicYN="N">Toll-Like Receptor 7</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Myositis</Keyword><Keyword MajorTopicYN="N">harakiri</Keyword><Keyword MajorTopicYN="N">membrane repair</Keyword><Keyword MajorTopicYN="N">mitochondria</Keyword><Keyword MajorTopicYN="N">muscle weakness</Keyword><Keyword MajorTopicYN="N">toll like receptors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31135059</ArticleId><ArticleId IdType="mid">NIHMS1583355</ArticleId><ArticleId IdType="pmc">PMC7219509</ArticleId><ArticleId IdType="doi">10.1002/path.5309</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coley W, Rayavarapu S, Nagaraju K. Role of non-immune mechanisms of muscle damage in idiopathic inflammatory myopathies. Arthritis Res Ther 2012; 14: 209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446443</ArticleId><ArticleId IdType="pubmed">22546362</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam PE, Weber-Sanders ML, Messner RP. Multiple viral determinants mediate myopathogenicity in coxsackievirus B1-induced chronic inflammatory myopathy. J Virol 2003; 77: 11849&#x2013;11854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC229355</ArticleId><ArticleId IdType="pubmed">14557670</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681&#x2013;1690.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672737</ArticleId></ArticleIdList></Reference><Reference><Citation>Svensson J, Holmqvist M, Lundberg IE, et al. Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case&#x2013;control study. Ann Rheum Dis 2017; 76: 1803&#x2013;1808.</Citation><ArticleIdList><ArticleId IdType="pubmed">28855175</ArticleId></ArticleIdList></Reference><Reference><Citation>Leff RL, Love LA, Miller FW, et al. Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. Lancet 1992; 339: 1192&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pubmed">1349938</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong D, Kea B, Pesich R, et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One 2012; 7: e29161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3250414</ArticleId><ArticleId IdType="pubmed">22235269</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007; 13: 59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1869622</ArticleId><ArticleId IdType="pubmed">17515957</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SA, Higgs BW, Morehouse C, et al. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun 2012; 13: 207&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">21881594</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgic H, Ytterberg SR, Amin S, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009; 60: 3436&#x2013;3446.</Citation><ArticleIdList><ArticleId IdType="pubmed">19877033</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowles N, Sewry C, Dubowitz V, et al. Dermatomyositis, polymyositis, and Coxsackie-B-virus infection. Lancet 1987; 329: 1004&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">2883345</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen ML, Pachman LM, Schneiderman R, et al. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheumatol 1986; 29: 1365&#x2013;1370.</Citation><ArticleIdList><ArticleId IdType="pubmed">3022759</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldfors A, Moslemi A, Jonasson L, et al. Mitochondrial abnormalities in inclusion-body myositis. Neurology 2006; 66: S49&#x2013;S55.</Citation><ArticleIdList><ArticleId IdType="pubmed">16432145</ArticleId></ArticleIdList></Reference><Reference><Citation>Basualto-Alarc&#x3cc;n C, Boz&#xe1;n M, Bevilacqua J, et al. AB0176 Mitochondrial dysfunction in idiopathic inflammatory myopathy derived myoblasts. Ann Rheum Dis 2017; 76: 1108.</Citation></Reference><Reference><Citation>Alhatou MI, Sladky JT, Bagasra O, et al. Mitochondrial abnormalities in dermatomyositis: characteristic pattern of neuropathology. J Mol Histol 2004; 35: 615&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">15614615</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo M, Chung SJ, Nonaka I. Perifascicular atrophic fibers in childhood dermatomyositis with particular reference to mitochondrial changes. J Neurol Sci 1988; 88: 133&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">2852214</ArticleId></ArticleIdList></Reference><Reference><Citation>Chariot P, Ruet E, Authier F-J, et al. Cytochrome c oxidase deficiencies in the muscle of patients with inflammatory myopathies. Acta Neuropathol 1996; 91: 530&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">8740235</ArticleId></ArticleIdList></Reference><Reference><Citation>Munters LA, Loell I, Ossipova E, et al. Endurance exercise improves molecular pathways of aerobic metabolism in patients with myositis. Arthritis Rheumatol 2016; 68: 1738&#x2013;1750.</Citation><ArticleIdList><ArticleId IdType="pubmed">26867141</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma N, Medikayala S, Defour A, et al. Use of quantitative membrane proteomics identifies a novel role of mitochondria in healing injured muscles. J Biol Chem 2012; 287: 30455&#x2013;30467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3436295</ArticleId><ArticleId IdType="pubmed">22778268</ArticleId></ArticleIdList></Reference><Reference><Citation>Horn A, Van der Meulen JH, Defour A, et al. Mitochondrial redox signaling enables repair of injured skeletal muscle cells. Sci Signal 2017; 10: eaaj1978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5949579</ArticleId><ArticleId IdType="pubmed">28874604</ArticleId></ArticleIdList></Reference><Reference><Citation>Vila MC, Rayavarapu S, Hogarth MW, et al. Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy. Cell Death Differ 2017; 24: 330&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299714</ArticleId><ArticleId IdType="pubmed">27834955</ArticleId></ArticleIdList></Reference><Reference><Citation>Munters LA, Dastmalchi M, Katz A, et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther 2013; 15: R83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978470</ArticleId><ArticleId IdType="pubmed">23941324</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaraju K, Ghimbovschi S, Rayavarapu S, et al. Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients. Rheumatology (Oxford) 2016; 55: 1673&#x2013;1680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5854096</ArticleId><ArticleId IdType="pubmed">27215813</ArticleId></ArticleIdList></Reference><Reference><Citation>Defour A, Sreetama S, Jaiswal JK. Imaging cell membrane injury and subcellular processes involved in repair. J Vis Exp 2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4089398</ArticleId><ArticleId IdType="pubmed">24686523</ArticleId></ArticleIdList></Reference><Reference><Citation>Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11: 621.</Citation><ArticleIdList><ArticleId IdType="pubmed">20683470</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris M, Thompson C. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell death and differentiation 2000; 7: 1182.</Citation><ArticleIdList><ArticleId IdType="pubmed">11175255</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhatou MI, Sladky JT, Bagasra O, et al. Mitochondrial abnormalities in dermatomyositis: characteristic pattern of neuropathology. J Mol Histol 2004; 35: 615&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">15614615</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew E, Araoz C, Sun C, et al. Dermatomyositis: ultrastructure of abnormal mitochondria in the skeletal muscle. Ann Clin Lab Sci 1977; 7: 29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">836001</ArticleId></ArticleIdList></Reference><Reference><Citation>Inohara N, Ding L, Chen S, et al. harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival&#x2010;promoting proteins Bcl&#x2010;2 and Bcl&#x2010;XL. EMBO J 1997; 16: 1686&#x2013;1694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1169772</ArticleId><ArticleId IdType="pubmed">9130713</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry SW, Norman JP, Barbieri J, et al. Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. Biotechniques 2011; 50: 98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3115691</ArticleId><ArticleId IdType="pubmed">21486251</ArticleId></ArticleIdList></Reference><Reference><Citation>Diebold SS. Recognition of viral single-stranded RNA by Toll-like receptors. Adv Drug Deliv Rev 2008; 60: 813&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pubmed">18241955</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho S-M, Johnson A, Tarapore P, et al. Environmental epigenetics and its implication on disease risk and health outcomes. ILAR J 2012; 53: 289&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4021822</ArticleId><ArticleId IdType="pubmed">23744968</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z, Yang Y, Chang C, et al. The epigenetic mechanism for discordance of autoimmunity in monozygotic twins. J Autoimmun 2017; 83: 43&#x2013;50..</Citation><ArticleIdList><ArticleId IdType="pubmed">28412046</ArticleId></ArticleIdList></Reference><Reference><Citation>Albayda J, Christopher-Stine L. Identifying statin-associated autoimmune necrotizing myopathy. Cleve Clin J Med 2014; 81: 736&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">25452351</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam P, Schmidt A, Ytterberg S, et al. Duration of virus persistence and its relationship to inflammation in the chronic phase of coxsackievirus B1-induced murine polymyositis. J Lab Clin Med 1994; 123: 346&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">8133145</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam P, Schmidt A, Ytterberg S, et al. Viral persistence during the developmental phase of Coxsackievirus B1-induced murine polymyositis. J Virol 1991; 65: 6654&#x2013;6660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC250734</ArticleId><ArticleId IdType="pubmed">1942249</ArticleId></ArticleIdList></Reference><Reference><Citation>Archard LC, Richardson PJ, Olsen E, et al. The role of Coxsackie B viruses in the pathogenesis of myocarditis, dilated cardiomyopathy and inflammatory muscle disease. Biochem Soc Symp 1987; 53: 51&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">2847741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ytterberg S Coxsackievirus B 1 induced murine polymyositis: acute infection with active virus is required for myositis. J Rheumatol 1987; 14: 12&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">3033235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ytterberg S, Mahowald M, Messner R. Coxsackievirus B 1-induced polymyositis. Lack of disease expression in nu/nu mice. J Clin Invest 1987; 80: 499&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC442263</ArticleId><ArticleId IdType="pubmed">3038960</ArticleId></ArticleIdList></Reference><Reference><Citation>Ytterberg S, Mahowald M, Messner R. T cells are required for coxsackievirus B1 induced murine polymyositis. J Rheumatol 1988; 15: 475&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">2837572</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques-Pons A, Yu Q, Rayavarapu S, et al. Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle. Hum Mol Genet 2014; 23: 2604&#x2013;2617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990161</ArticleId><ArticleId IdType="pubmed">24368419</ArticleId></ArticleIdList></Reference><Reference><Citation>Triantafilou K, Orthopoulos G, Vakakis E, et al. Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll&#x2010;like receptor (TLR) 8&#x2010;dependent. Cell Microbiol 2005; 7: 1117&#x2013;1126.</Citation><ArticleIdList><ArticleId IdType="pubmed">16008579</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Dalakas MC. Expression of human IAP-like protein in skeletal muscle: a possible explanation for the rare incidence of muscle fiber apoptosis in T-cell mediated inflammatory myopathies. J Neuroimmunol 2000; 106: 1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10814776</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaraju K, Casciola-Rosen L, Rosen A, et al. The inhibition of apoptosis in myositis and in normal muscle cells. J Immunol 2000; 164: 5459&#x2013;5465.</Citation><ArticleIdList><ArticleId IdType="pubmed">10799913</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaraju K, Casciola&#x2010;Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005; 52: 1824&#x2013;1835.</Citation><ArticleIdList><ArticleId IdType="pubmed">15934115</ArticleId></ArticleIdList></Reference><Reference><Citation>Alger HM, Raben N, Pistilli E, et al. The role of TRAIL in mediating autophagy in myositis skeletal muscle: a potential nonimmune mechanism of muscle damage. Arthritis Rheum 2011; 63: 3448&#x2013;3457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203318</ArticleId><ArticleId IdType="pubmed">21769834</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattingre S, Tassa A, Qu X, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005; 122: 927&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">16179260</ArticleId></ArticleIdList></Reference><Reference><Citation>Rygiel KA, Miller J, Grady JP, et al. Mitochondrial and inflammatory changes in sporadic inclusion body myositis. Neuropathol Appl Neurobiol 2015; 41: 288&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4833191</ArticleId><ArticleId IdType="pubmed">24750247</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland AA, Voeltz GK. Endoplasmic reticulum&#x2013;mitochondria contacts: function of the junction. Nat Rev Mol Cell Biol 2012; 13: 607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111635</ArticleId><ArticleId IdType="pubmed">22992592</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>